Fig. 1 · Structure

Documents & Downloads

Butein

Cat. No. A12448 CAS 487-52-5
Butein is a plant polyphenol that acts as a specific protein tyrosine kinase inhibitor.

In Stock

Free Aliquoting for Your Order

Tell us your preferred amount per vial. We’ll confirm the options.

Biological Activity

Target & Activity

Target Activity Value
EGFR 16 μM (IC50, in HepG2 cells)
PDE4 IC50 10.4 μM

Cellular Effect

Cell Line Activity Value Description Reference
A549 IC50 > 20 μM Inhibition of TNFalpha induced NF-kappaB activation in human A549 cells by luciferase reporter gene assay [PMID: 19883086]
BV-2 IC50 10.9 μM Antiinflammatory activity in mouse BV2 cells assessed as inhibition of LPS-induced nitric oxide production pretreated for 1 hr followed by LPS addition and measured after 24 hrs by Griess assay [PMID: 28923363]
BV-2 IC50 4.3 μM Inhibition of LPS-induced NO production in mouse BV2 cells by Griess assay [PMID: 27287369]
C2C12 IC50 18.99 μg/mL Cytotoxicity against mouse C2C12 cells assessed as reduction in cell viability by MTT assay [PMID: 33412152]
K562 IC50 38 μM Inhibition of NF-kappaB transactivation in TNF-alpha-stimulated human K562 cells preincubated for 2 hrs followed by TNF-alpha challenge measured after 6 hrs by dual luciferase reporter gene assay [PMID: 24775915]
KB CC50 9.1 μM Compound concentration required to reduce the exponential growth of KB cells by 50% [PMID: 9767632]
Macrophage IC50 43.3 μM Inhibition of LPS stimulated TNF alpha production in Balb/c mouse peritoneal macrophages measured by ELISA plate reader method [PMID: 32361286]
MT4 CC50 5.3 μM Compound concentration required to reduce the exponential growth of MT-4 cells by 50% [PMID: 9767632]
NIH3T3 IC50 > 20 μM Inhibition of cobalt chloride-induced HIF-1 activation expressed in mouse NIH3T3 cells after 8 hrs by luciferase reporter gene assay [PMID: 21112783]
RAW264.7 IC50 35.1 μM Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced nitric oxide production after 24 hrs by Griess assay [PMID: 23743282]
RAW264.7 IC50 5.3 μM Inhibition of LPS-induced NO production in mouse RAW264.7 cells by Griess assay [PMID: 27287369]

11 records · Scroll to view more

Butein Research Summary

This section summarizes 3 in vitro studies and 1 in vivo study of Butein from 3 published references. In vitro models include HeLa human cervical carcinoma cells; HeLa cells.

Butein In Vitro Studies

In HeLa human cervical carcinoma cells, Butein alone inhibited cell growth in a dose- and time-dependent manner. In a separate HeLa cell study, Butein alone slightly increased the percentage of apoptotic cells compared with untreated controls. In breast cancer cell–fibroblast cocultures, Butein significantly reduced clonogenic growth compared with cell culture medium alone with no drug. [1,2]

Literature-reported observations and conditions; not Adooq-tested protocols or general treatment recommendations.

Growth inhibition in cervical carcinoma cells

Cell-based study · HeLa human cervical carcinoma cells [1]

In HeLa human cervical carcinoma cells, Butein alone inhibited cell growth in a dose- and time-dependent manner, assessed by MTT assay.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
cell viability was determined by MTT assayReported result Butein (10, 20 and 40 µm) for different periods of time: Treatment with both butein and cisplatin alone inhibited cell growth in a dose- and time-dependent manner.[1]

Literature-Reported Treatment Conditions

Treatment concentration
10, 20 and 40 µm
Exposure duration
different periods of time
Vehicle
dimethyl sulfoxide (DMSO)
Reported limits
Not stated in the sentences used: route.
Methods and source locations

Compound reported in the paper: Butein

Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.

Materials and methods > Drugs and antibodies (S1); Materials and methods > Cell culture (S5); Materials and methods > Cell viability assay (S10, S13); Results > Butein synergistically enhances the cell growth inhibitory and apoptosis-inducing effects of cisplatin (S62, S63); Figure 1 legend (S105, S106)

cell viability was determined by MTT assay: cell viability was determined by MTT assay; comparator: control (untreated) — Results > Butein synergistically enhances the cell growth inhibitory and apoptosis-inducing effects of cisplatin (S62, S63); Figure 1 legend (S105)

Reduced clonogenic growth in breast cancer cell–fibroblast coculture

Cell-based study · A monolayer of normal fibroblasts was seeded with 100 UACC-812 tumor cells/well [2]

In cocultures of breast cancer cells and normal fibroblasts, Butein significantly reduced clonogenic growth compared with cell culture medium alone with no drug.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
numbers of colonies of 12 or more tumor cellsclonogenic growth Co-culture of breast cancer cells and fibroblasts; butein (2 μg/mL): one small colony of tumor cells visible in one of three wells containing butein[2]

Literature-Reported Treatment Conditions

Treatment concentration
2 μg/mL
Exposure duration
At intervals of 3–4 days, old medium was removed and replaced with fresh medium containing the drugs. After 14 days
Method
medium supplemented with various modulators of fibroblast function
Vehicle
dimethylsulfoxide
Co-treatment
Other interventions in this design: normal fibroblasts A monolayer; UACC-812 tumor cells 100 UACC-812 tumor cells/well. Compound effect isolated by the comparison: compared to the control (cell culture medium alone with no drug).
Methods and source locations

Compound reported in the paper: Butein

Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.

Methods > Clonogenic assay (S8); Methods > Co-culture with fibroblast modulators (Experiment 1) (S11, S12, S13, S14, S15); Results > Co-culture with fibroblast modulators (S31, S32); Figure 3 legend (S44)

numbers of colonies of 12 or more tumor cells: numbers of colonies of 12 or more tumor cells; comparator: cell culture medium alone with no drug — Methods > Co-culture with fibroblast modulators (Experiment 1) (S12, S15); Results > Co-culture with fibroblast modulators (S31, S32); Figure 3 legend (S44)

Apoptosis in HeLa cells

Cell-based study · HeLa cells [1]

In HeLa cells, Butein alone slightly increased the percentage of apoptotic cells compared with untreated controls, assessed by flow cytometry using PI/Annexin V staining.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Apoptosis was measured by flow cytometry PI/Annexin V stainingReported result Butein (20 µM) for 48 h: treatment with butein or cisplatin alone slightly increased the percentage of apoptotic cells compared to the untreated controls.[1]

Literature-Reported Treatment Conditions

Treatment concentration
20 µM
Exposure duration
48 h
Vehicle
dimethyl sulfoxide (DMSO)
Reported limits
Not stated in the sentences used: route.
Methods and source locations

Compound reported in the paper: Butein

Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.

Materials and methods > Drugs and antibodies (S1); Materials and methods > Apoptosis assay (S23); Results > Butein synergistically enhances the cell growth inhibitory and apoptosis-inducing effects of cisplatin (S66); Figure 1 legend (S107, S110)

Apoptosis was measured by flow cytometry PI/Annexin V staining: Apoptosis was measured by flow cytometry PI/Annexin V staining; comparator: untreated controls — Results > Butein synergistically enhances the cell growth inhibitory and apoptosis-inducing effects of cisplatin (S66); Figure 1 legend (S107, S110)

Butein In Vivo Studies

Butein was administered by intragastric gavage during the modeling period in male mice with DSS-induced colitis. Compared with the DSS group, Butein-treated mice exhibited less weight loss and a lower disease activity index score. [3]

Weight loss and disease activity in experimental colitis

Animal study · DSS-induced colitis model; C57BL/6 male mice; n = 10 for each group [3]

In male mice with DSS-induced colitis, Butein was administered by intragastric gavage during the modeling period. Compared with the DSS group, Butein-treated mice exhibited less weight loss and a lower disease activity index score.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
disease activity index (DAI) scoreReported result Mice received butein (10, or 20 mg/kg) by intragastric gavage during the modeling period. Compared with those in the DSS group, butein-treated mice exhibited less weight loss and a lower DAI score.[3]

Conditions shared by the study groups

Route
intragastric gavage
Treatment course
during the modeling period; for 9 days
Study groups and reported outcomes
Group / doseComparatorObserved resultReference
Butein 10 or 20 mg/kg body weightDSS groupMice received butein (10, or 20 mg/kg) by intragastric gavage during the modeling period. Compared with those in the DSS group, butein-treated mice exhibited less weight loss and a lower DAI score.[3]
Butein 10 or 20 mg/kg body weight
Model: DSS-induced colitis model; C57BL/6 male mice; n = 10 for each group
Reported limits: Not stated in the sentences used: vehicle.
Methods and source locations

Compound reported in the paper: Butein

Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.

Materials and methods > DSS-induced colitis mouse model (S47, S48, S50); Results > Butein alleviates DSS-induced colitis (S135, S145, S146, S147)

disease activity index (DAI) score: disease activity index (DAI) score; comparator: DSS group — Materials and methods > DSS-induced colitis mouse model (S50); Results > Butein alleviates DSS-induced colitis (S135, S146)

Butein 10 or 20 mg/kg body weight · Materials and methods > DSS-induced colitis mouse model (S48); Results > Butein alleviates DSS-induced colitis (S135, S145, S146)

Specifications

Manufacturer Adooq Bioscience
Actions Inhibitor
CAS Number 487-52-5
Formula C15H12O5
Molecular Weight 272.3
Synonyms 2',3,4,4'-Tetrahydroxychalcone
SMILES
C1=CC(=C(C=C1/C=C/C(=O)C2=C(C=C(C=C2)O)O)O)O

Storage & Solubility

In Vitro Solubility

Reported Solubility

SolventReported Solubility
DMSO 54 mg/mL (198.35 mM)
Water Insoluble
Ethanol 54 mg/mL (198.35 mM)

Preparing Stock Solutions

Stock preparation is unavailable for this product molecular weight.

Calculated stock concentrations do not establish solvent solubility. Refer to the reported solubility data for experimental guidance.

Storage

Store powder at -20°C, keep desiccated.
In powder form, the chemical is stable for 36 months.
In solution, store at -20°C and use within 1 month to prevent loss of potency. Aliquot to avoid multiple freeze/thaw cycles.

Butein Research References

  1. [1] Zhang L, Yang X, Li X, et al. Butein sensitizes HeLa cells to cisplatin through the AKT and ERK/p38 MAPK pathways by targeting FoxO3a. Int J Mol Med (2015). PMID: 26310353 DOI: 10.3892/ijmm.2015.2324 Source material
  2. [2] Samoszuk M, Tan J, Chorn G. The chalcone butein from Rhus verniciflua Stokes inhibits clonogenic growth of human breast cancer cells co-cultured with fibroblasts. BMC Complement Altern Med (2005). PMID: 15757513 DOI: 10.1186/1472-6882-5-5 Source material
  3. [3] Liao W, Li Y, Liu J, et al. Homotherapy for heteropathy: therapeutic effect of Butein in NLRP3-driven diseases. Cell Commun Signal (2024). PMID: 38849890 DOI: 10.1186/s12964-024-01695-7 Source material

Added to your cart

View Cart Checkout
Loading...